Skip to main content

Advertisement

SpringerLink
Log in

Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

Current algorithms for automated computer interpretation of optical coherence tomography (OCT) imaging of patients suffering from neovascular age-related macular degeneration (AMD) mostly rely on fluid detection. However, fluid detection itself and correct interpretation of the fluid currently limits diagnostic accuracy. We therefore performed a detailed analysis of the requirements that would have to be met for fluid detection approaches. We further investigated if monitoring retinal volume would be a viable alternative to detect disease activity.

Methods

Retrospective analysis and manual grading of 764 OCT volume scans of 44 patients with exudative AMD treated with intravitreal anti-VEGF injections at a pro-re-nata (PRN) treatment regimen for at least 24 months.

Results

Detection of subretinal fluid (SRF) or intraretinal fluid (IRF) alone is not sufficient for disease detection. A combination of SRF and IRF can detect disease activity with a sensitivity of 98.6% and a specificity of 82%. With further characterization of IRF into exudative and degenerative cysts, specificity can be increased to 100%. However, correct characterization is currently not achieved by published fluid detection approaches. Change of macular retinal volume (MRV) can depict disease activity with sensitivity of 88.4% and specificity of 89.6%. Combination with the detection of SRF can further improve diagnostic accuracy to a specificity of 93.3% and sensitivity of 93.9% without relying on IRF or IRF characterization.

Conclusion

Fluid detection without further characterization is not sufficient for AMD monitoring. Either further distinction between exudative and degenerative cysts is necessary, or other activity markers have to be taken into account. MRV offers good potential to fill this diagnostic gap and might become an important monitoring marker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

    Article  PubMed  CAS  Google Scholar 

  2. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398. https://doi.org/10.1016/j.ophtha.2012.03.053

    Article  Google Scholar 

  3. Schmidt-Erfurth U, Eldem B, Guymer R et al (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831–839. https://doi.org/10.1016/j.ophtha.2010.09.004

    Article  PubMed  Google Scholar 

  4. Ho AC, Busbee BG, Regillo CD et al (2014) Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121:2181–2192. https://doi.org/10.1016/j.ophtha.2014.05.009

    Article  PubMed  Google Scholar 

  5. Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. https://doi.org/10.1016/j.ophtha.2014.07.041

    Article  PubMed  Google Scholar 

  6. Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144–1167. https://doi.org/10.1136/bjophthalmol-2014-305702

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pauleikhoff D, Bertram B, Holz FG et al (2013) Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012. Klin Monatsbl Augenheilkd 230:170–177. https://doi.org/10.1055/s-0032-1328113

    Article  PubMed  CAS  Google Scholar 

  8. Gianniou C, Dirani A, Jang L, Mantel I (2015) Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranizubimab: functional and structural outcome. Retina 35:1195–1201. https://doi.org/10.1097/IAE.0000000000000465

    Article  PubMed  CAS  Google Scholar 

  9. Sing T, Sander O, Beerenwinkel N, Lengauer T (2005) ROCR: visualizing classifier performance in R. Bioinformatics 21:3940–3941. https://doi.org/10.1093/bioinformatics/bti623

    Article  PubMed  CAS  Google Scholar 

  10. Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583. https://doi.org/10.1016/j.ajo.2007.01.028

    Article  PubMed  CAS  Google Scholar 

  11. Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24. https://doi.org/10.1016/j.preteyeres.2015.07.007

    Article  PubMed  CAS  Google Scholar 

  12. Zweifel SA, Engelbert M, Laud K et al (2009) Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol 127:1596–1602. https://doi.org/10.1001/archophthalmol.2009.326

    Article  PubMed  Google Scholar 

  13. Schaal KB, Freund KB, Litts KM et al (2015) Outer retinal tubulation in advanced age-related macular degeneration: optical coherence tomographic findings correspond to histology. Retina (Philadelphia, Pa) 35:1339–1350. https://doi.org/10.1097/IAE.0000000000000471

    Article  Google Scholar 

  14. Espina M, Arcinue CA, Ma F et al (2016) Outer retinal tubulations response to anti-VEGF treatment. Br J Ophthalmol 100:819–823. https://doi.org/10.1136/bjophthalmol-2015-307141

    Article  PubMed  Google Scholar 

  15. Chakravarthy U, Goldenberg D, Young G et al (2016) Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology 123:1731–1736. https://doi.org/10.1016/j.ophtha.2016.04.005

    Article  PubMed  Google Scholar 

  16. Xu X, Lee K, Zhang L et al (2015) Stratified sampling voxel classification for segmentation of intraretinal and subretinal fluid in longitudinal clinical OCT data. IEEE Trans Med Imaging. https://doi.org/10.1109/TMI.2015.2408632

  17. Wang C, Li Y, Wang YX (2017) Automatic choroidal layer segmentation using Markov random field and level set method. J biomed health inform. https://doi.org/10.1109/JBHI.2017.2675382

  18. Sabouri MR, Kazemnezhad E, Hafezi V (2016) Assessment of macular thickness in healthy eyes using cirrus HD-OCT: a cross-sectional study. Med Hypothesis Discov Innov Ophthalmol 5:104–111

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

The German Federal Ministry of Education and Research (BMBF) provided financial support in the form of a research grand (Grant No. 13N13766).

The sponsor had no role in the design or conduct of this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Christian-Albrechts-University of Kiel, University Medical Center, Arnold-Heller-Strasse 3, 24105, Kiel, Germany

    Claus von der Burchard, Felix Treumer, Christoph Ehlken, Stefan Koinzer, Konstantine Purtskhvanidze, Jan Tode & Johann Roider

Authors
  1. Claus von der Burchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Treumer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Ehlken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Koinzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konstantine Purtskhvanidze
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan Tode
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johann Roider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claus von der Burchard.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

von der Burchard, C., Treumer, F., Ehlken, C. et al. Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 256, 1623–1629 (2018). https://doi.org/10.1007/s00417-018-4040-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-018-4040-7

Keywords

Search

Navigation